All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
Relapsing-remitting Multiple Sclerosis
Active Secondary Progressive Multiple Sclerosis
Jun 30, 2021
Jul 31, 2026
99 Years and older (Child, Adult, Older Adult)
Prospective observational cohort study. There is no treatment allocation.
Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients
Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug)
Patients with a history of hypersensitivity to any of the Kesimpta ingredients